NO20054714L - Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom - Google Patents
Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdomInfo
- Publication number
- NO20054714L NO20054714L NO20054714A NO20054714A NO20054714L NO 20054714 L NO20054714 L NO 20054714L NO 20054714 A NO20054714 A NO 20054714A NO 20054714 A NO20054714 A NO 20054714A NO 20054714 L NO20054714 L NO 20054714L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- procedures
- preventing
- cognitive impairments
- alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45458903P | 2003-03-14 | 2003-03-14 | |
PCT/GB2004/000983 WO2004080459A1 (fr) | 2003-03-14 | 2004-03-08 | Methode permettant de traiter une deficience cognitive legere et de prevenir ou de retarder l'apparition la maladie d'alzheimer |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054714D0 NO20054714D0 (no) | 2005-10-13 |
NO20054714L true NO20054714L (no) | 2005-11-16 |
Family
ID=32990914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054714A NO20054714L (no) | 2003-03-14 | 2005-10-13 | Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060241133A1 (fr) |
EP (1) | EP1605940A1 (fr) |
JP (1) | JP2006520371A (fr) |
KR (1) | KR20050109990A (fr) |
CN (1) | CN1794992A (fr) |
AU (1) | AU2004218871A1 (fr) |
BR (1) | BRPI0408295A (fr) |
CA (1) | CA2518886A1 (fr) |
IS (1) | IS8004A (fr) |
MX (1) | MXPA05009850A (fr) |
NO (1) | NO20054714L (fr) |
RU (1) | RU2005131845A (fr) |
WO (1) | WO2004080459A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0313772D0 (en) * | 2003-06-13 | 2003-07-23 | Merck Sharp & Dohme | Therapeutic treatment |
CA2629402C (fr) | 2005-11-21 | 2011-07-26 | Amgen Inc. | Modulateurs de beta-secretase et procedes d'utilisation associes |
US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7838676B2 (en) * | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
WO2008147544A1 (fr) | 2007-05-25 | 2008-12-04 | Amgen Inc. | Composés d'hydroxyéthylamine substitués en tant que modulateurs de la bêta-sécrétase et méthodes d'utilisation |
TW200901991A (en) | 2007-05-25 | 2009-01-16 | Amgen Inc | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
BRPI0918449A2 (pt) * | 2008-09-11 | 2019-09-24 | Amgen Inc | compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso |
WO2011063233A1 (fr) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Composés amino hétéroaryles comme modulateurs de la bêta-secrétase et procédés d'utilisation |
WO2011063272A1 (fr) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Composés amino hétéroaryliques comme modulateurs de bêta-sécrétase et procédés d'utilisation |
US8735384B2 (en) | 2010-01-19 | 2014-05-27 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
JP5584352B2 (ja) | 2010-03-15 | 2014-09-03 | アムジエン・インコーポレーテツド | β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途 |
AU2011227511B2 (en) | 2010-03-15 | 2014-02-20 | Amgen Inc. | Spiro-tetracyclic ring compounds as Beta - secretase modulators |
US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
WO2013044092A1 (fr) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Composés d'amino-oxazines et d'amino-dihydrothiazine comme modulateurs de sécrétase bêta et procédés d'utilisation |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
LU92126B1 (fr) * | 2012-12-31 | 2014-07-01 | Cesa Alliance Sa | Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902680A (en) * | 1984-10-29 | 1990-02-20 | Chaovanee Aroonsakul | Treating central nervous system diseases |
NZ258412A (en) * | 1992-12-11 | 1997-01-29 | Merck & Co Inc | Spiro-fused piperidine derivatives and pharmaceutical compositions |
AU5486396A (en) * | 1995-04-19 | 1996-11-07 | Merck & Co., Inc. | Process for the preparation of spiroindolines |
US6028196A (en) * | 1995-10-27 | 2000-02-22 | Merck & Co., Inc. | Process for the preparation of a growth hormone secretagogue |
US5767124A (en) * | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
AU711884B2 (en) * | 1996-05-07 | 1999-10-21 | Merck & Co., Inc. | Enhancement of sleep with a growth hormone secretagogue |
US6046333A (en) * | 1996-10-25 | 2000-04-04 | Merck & Co., Inc. | Convergent process for the preparation of a growth hormone secretagogue |
CN1261158C (zh) * | 1998-09-03 | 2006-06-28 | 诺兰兹公司 | 生长激素在制备用于诱导神经保护作用的药剂中的应用 |
US6849597B2 (en) * | 1999-12-28 | 2005-02-01 | Kaken Pharmaceutical Co., Ltd. | Neuroprotective drug |
EP1149583A3 (fr) * | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinaison des antagonistes de la facteur de la liberation de la corticotropin et des secrétagogues de l hormone de croissance |
-
2004
- 2004-03-08 RU RU2005131845/15A patent/RU2005131845A/ru not_active Application Discontinuation
- 2004-03-08 CA CA002518886A patent/CA2518886A1/fr not_active Abandoned
- 2004-03-08 EP EP04718341A patent/EP1605940A1/fr not_active Withdrawn
- 2004-03-08 JP JP2006505929A patent/JP2006520371A/ja not_active Withdrawn
- 2004-03-08 KR KR1020057017128A patent/KR20050109990A/ko not_active Application Discontinuation
- 2004-03-08 BR BRPI0408295-8A patent/BRPI0408295A/pt not_active Application Discontinuation
- 2004-03-08 CN CNA2004800069622A patent/CN1794992A/zh active Pending
- 2004-03-08 AU AU2004218871A patent/AU2004218871A1/en not_active Abandoned
- 2004-03-08 MX MXPA05009850A patent/MXPA05009850A/es unknown
- 2004-03-08 WO PCT/GB2004/000983 patent/WO2004080459A1/fr not_active Application Discontinuation
- 2004-03-08 US US10/549,839 patent/US20060241133A1/en not_active Abandoned
-
2005
- 2005-08-29 IS IS8004A patent/IS8004A/is unknown
- 2005-10-13 NO NO20054714A patent/NO20054714L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP1605940A1 (fr) | 2005-12-21 |
CN1794992A (zh) | 2006-06-28 |
KR20050109990A (ko) | 2005-11-22 |
MXPA05009850A (es) | 2005-12-06 |
AU2004218871A1 (en) | 2004-09-23 |
NO20054714D0 (no) | 2005-10-13 |
RU2005131845A (ru) | 2006-02-10 |
US20060241133A1 (en) | 2006-10-26 |
CA2518886A1 (fr) | 2004-09-23 |
IS8004A (is) | 2005-08-29 |
BRPI0408295A (pt) | 2006-03-07 |
JP2006520371A (ja) | 2006-09-07 |
WO2004080459A1 (fr) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054714L (no) | Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
GB0225475D0 (en) | Therapeutic agents | |
GB0005251D0 (en) | Therapeutic compounds | |
IL171977A (en) | Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same | |
GB0223038D0 (en) | Therapeutic compounds | |
EA200400881A1 (ru) | Азаарилпиперазины | |
SE0202462D0 (sv) | Novel use | |
GB0318447D0 (en) | Therapeutic agents | |
DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
JO2282B1 (en) | Oxazole derivatives | |
GB0225474D0 (en) | Therapeutic agents | |
MXPA05010958A (es) | Derivados indazol como inhibidores jnk. | |
WO2006067165A3 (fr) | Medicaments pour le traitement ou la prevention de maladies fibrotiques | |
WO2004029031A3 (fr) | Agents therapeutiques utiles dans le traitement de la douleur | |
ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
GB0112348D0 (en) | Compounds | |
EA200401114A3 (ru) | Замещённые гидроксиэтиламины | |
SE0202429D0 (sv) | Novel Compounds | |
UA83233C2 (ru) | Замещенный 2-аминотетралин для лечения депрессии | |
NO20052698L (no) | 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser. | |
NO20065079L (no) | Materialer og metoder for behandling av koaguleringssykdommer | |
ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
TW200637544A (en) | Medicaments for the treatment or prevention of fibrotic diseases |